RT Journal Article
T1 CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventions.
A1 Rossello, Xavier
A1 Rodriguez-Sinovas, Antonio
A1 Vilahur, Gemma
A1 Crisóstomo, Verónica
A1 Jorge, Inmaculada
A1 Zaragoza, Carlos
A1 Zamorano, José L
A1 Bermejo, Javier
A1 Ordoñez, Antonio
A1 Boscá, Lisardo
A1 Vázquez, Jesús
A1 Badimón, Lina
A1 Sánchez-Margallo, Francisco M
A1 Fernández-Avilés, Francisco
A1 Garcia-Dorado, David
A1 Ibanez, Borja
AB Despite many cardioprotective interventions have shown to protect the heart against ischemia/reperfusion injury in the experimental setting, only few of them have succeeded in translating their findings into positive proof-of-concept clinical trials. Controversial and inconsistent experimental and clinical evidence supports the urgency of a disruptive paradigm shift for testing cardioprotective therapies. There is a need to evaluate experimental reproducibility before stepping into the clinical arena. The CIBERCV (acronym for Spanish network-center for cardiovascular biomedical research) has set up the "Cardioprotection Large Animal Platform" (CIBER-CLAP) to perform experimental studies testing the efficacy and reproducibility of promising cardioprotective interventions based on a pre-specified design and protocols, randomization, blinding assessment and other robust methodological features. Our first randomized, control-group, open-label blinded endpoint experimental trial assessing local ischemic preconditioning (IPC) in a pig model of acute myocardial infarction (n = 87) will be carried out in three separate sets of experiments performed in parallel by three laboratories. Each set aims to assess: (A) CMR-based outcomes; (B) histopathological-based outcomes; and (C) protein-based outcomes. Three core labs will assess outcomes in a blinded fashion (CMR imaging, histopathology and proteomics) and 2 methodological core labs will conduct the randomization and statistical analysis.
YR 2019
FD 2019-12-30
LK http://hdl.handle.net/10668/14905
UL http://hdl.handle.net/10668/14905
LA en
DS RISalud
RD Apr 12, 2025